Madrigal Pharmaceuticals, Inc.
MDGL Nasdaq
SEC CIK 1157601
Follow Madrigal Pharmaceuticals
Weekly email: filings, results
Revenue, last quarter
$431.3M
+50.1% vs same quarter last year
Net income
$55.4M
+148.6% vs same quarter last year
EPS, diluted
$1.83
+145.6% vs same quarter last year
Operating cash flow
$120.6M
+51% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $958.4M | −$288.3M |
| FY24 | $180.1M | −$465.9M |
| FY23 | $0 | −$373.6M |
| FY22 | $0 | −$295.3M |
| FY21 | $0 | −$241.8M |
| FY20 | $0 | −$202.2M |
| FY19 | $0 | −$83.9M |
| FY18 | $0 | −$32.8M |
| FY17 | $0 | −$31.2M |
| FY16 | - | −$26.4M |
| FY15 | - | −$6.8M |
| FY14 | - | −$86.2M |
| FY13 | - | −$90.2M |
| FY12 | $147K | −$62.8M |
| FY11 | - | −$47.4M |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY25 | −31.3% | −30.1% |
| FY24 | −276.4% | −258.6% |
| FY23 | - | - |
| FY22 | - | - |
| FY21 | - | - |
| FY20 | - | - |
| FY19 | - | - |
| FY18 | - | - |
| FY17 | - | - |
| FY16 | - | - |
| FY15 | - | - |
| FY14 | - | - |
| FY13 | - | - |
| FY12 | −41456.5% | −42714.3% |
| FY11 | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$190M |
| FY24 | −$457M |
| FY23 | −$325.7M |
| FY22 | −$225.1M |
| FY21 | −$184.1M |
| FY20 | −$157.9M |
| FY19 | −$41.8M |
| FY18 | −$25.5M |
| FY17 | −$22.4M |
| FY16 | −$17.6M |
| FY15 | −$3.2M |
| FY14 | −$79.1M |
| FY13 | −$78.2M |
| FY12 | −$54.6M |
| FY11 | −$48M |
- Madrigal Pharmaceuticals
- Healthcare median
Show the numbers
| Year | Madrigal Pharmaceuticals | Healthcare median |
|---|---|---|
| FY25 | −30.1% | −30.6% |
| FY24 | −258.6% | −47% |
| FY23 | - | −58% |
| FY22 | - | −80.4% |
| FY21 | - | −71.8% |
| FY20 | - | −62.2% |
| FY19 | - | −46.2% |
| FY18 | - | −49.6% |
| FY17 | - | −45.9% |
| FY16 | - | −36% |
| FY15 | - | −37.8% |
| FY14 | - | −35.5% |
| FY13 | - | −37.1% |
| FY12 | −42714.3% | −29.1% |
| FY11 | - | −27.9% |